Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is clear cell sarcoma of the kidney?
Clear cell sarcoma of the kidney (CCSK) is a rare childhood kidney cancer, distinct from the much more common Wilms tumor and from the clear cell sarcoma that occurs in soft tissue of adults. It is the second most common malignant kidney tumor of childhood, usually diagnosed in toddlers and young children, and it is sometimes called the 'bone-metastasizing renal tumor of childhood' because of its notable tendency to spread to bone — though it can also spread to the brain, lungs, lymph nodes, and other sites. Many cases carry a specific genetic change (an internal duplication in the BCOR gene) that helps confirm the diagnosis. Because CCSK is aggressive, it is treated with intensive, coordinated, multimodality therapy. Surgery to remove the affected kidney (nephrectomy) is combined with chemotherapy that includes doxorubicin, and radiation is given to the tumor bed for most patients. Children are treated on pediatric oncology protocols, typically through cooperative groups such as the Children's Oncology Group, which has steadily improved outcomes. With modern combined treatment, the great majority of children with localized disease are cured, and even children with spread can do well. Because relapses — including late ones in bone and brain — can occur, long-term follow-up is important.
The main types
Doctors group clear cell sarcoma of the kidney by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Localized clear cell sarcoma of the kidney | Cancer confined to the kidney or nearby tissue. Treated with surgery, chemotherapy including doxorubicin, and radiation to the tumor bed, with high cure rates. |
| Metastatic clear cell sarcoma of the kidney | Cancer that has spread, classically to bone but also to the brain, lungs, or lymph nodes. Treated with more intensive chemotherapy and radiation to involved sites. |
Staging, in plain terms
Clear cell sarcoma of the kidney is staged using the pediatric renal-tumor system used for childhood kidney cancers (stages I through IV), based on how far the tumor extends, whether it was completely removed, whether lymph nodes are involved, and whether it has spread to distant sites such as bone. This is different from the TNM system used in adults. The stage, along with how the tumor responds to treatment, guides the intensity of chemotherapy and the use of radiation.
| Children's Oncology Group renal tumor staging (stages I–IV), not adult TNM | What it generally means |
|---|---|
| Stage I–II (confined, removable) | Tumor limited to the kidney and completely removed by surgery. Treated with surgery, chemotherapy, and radiation to the tumor bed; cure rates are high. |
| Stage III (regional spread or incomplete removal) | Tumor extends beyond the kidney, involves lymph nodes, or was not fully removed. Treated with surgery, chemotherapy, and radiation to the affected area. |
| Stage IV (distant spread) | Spread to distant sites, classically bone but also brain or lungs. Treated with intensive chemotherapy plus radiation to metastatic sites; many children still do well. |
The standard of care
Clear Cell Sarcoma of the Kidney is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery (nephrectomy)
Removing the affected kidney and its surrounding tissue, with sampling of nearby lymph nodes, is the first step and confirms the diagnosis.
Intensive chemotherapy (including doxorubicin)
Multi-drug chemotherapy with doxorubicin is a key part of treatment because this cancer is aggressive and prone to spread; it markedly improves survival.
Radiation to the tumor bed
Radiation to the area where the tumor was removed is given for most patients to lower the chance of local recurrence, and to sites of spread when present.
Treatment on pediatric protocols with long-term follow-up
Care through cooperative-group protocols (such as the Children's Oncology Group) standardizes and optimizes treatment; long-term follow-up watches for late relapse in bone and brain.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide and survive, while healthy cells repair themselves more effectively. In clear cell sarcoma of the kidney, radiation is given to the area where the tumor was removed — and to sites of spread, such as bone — to lower the chance the cancer comes back, working alongside surgery and chemotherapy. Because the patients are young children whose bodies are still growing, radiation is planned very carefully to use the lowest effective dose and to shield developing tissues; in some centers proton therapy is used because it can spare healthy organs near the treatment area. Radiation is given as short, painless daily sessions and leaves no radioactivity in the child's body, so the child remains safe to be around family and other children. Combined with surgery and chemotherapy, radiation is part of the modern treatment that has greatly improved survival.
The main ways radiation is delivered for clear cell sarcoma of the kidney:
Surgery
Removal of the affected kidney (nephrectomy) with lymph-node sampling removes the bulk of the tumor and provides tissue for diagnosis and staging.
Chemotherapy
Combination chemotherapy that includes doxorubicin treats the whole body, addressing this tumor's tendency to spread and substantially improving cure rates.
Radiation
Focused radiation to the tumor bed (and to sites of spread such as bone) lowers the chance of recurrence; in young children, careful planning protects growing tissues, and proton therapy may be used to spare developing organs.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Doxorubicin-based chemotherapy improved survival: Cooperative-group trials established that adding doxorubicin to chemotherapy markedly improved survival for clear cell sarcoma of the kidney, transforming it from a high-risk tumor into one that is curable in most children.[1]
National Wilms Tumor Study / Children's Oncology Group renal tumor trials
BCOR internal tandem duplication as a diagnostic marker: Molecular studies identified recurrent internal duplications in the BCOR gene as a hallmark of clear cell sarcoma of the kidney, improving diagnostic accuracy and distinguishing it from other childhood kidney tumors.[2]
Pediatric renal tumor molecular pathology literature (2015–2023)
Late relapse to bone and brain supports prolonged follow-up: Long-term data document this tumor's tendency for delayed relapse, including in bone and brain, supporting extended surveillance after treatment completion.[3]
Childhood renal tumor follow-up studies (2016–2024)
Common questions
How is this different from Wilms tumor? Clear cell sarcoma of the kidney is a separate, rarer childhood kidney cancer that is more aggressive than Wilms tumor and has a notable tendency to spread to bone. It carries a different genetic change and is treated with more intensive chemotherapy that includes doxorubicin, plus radiation. Telling the two apart on pathology is important because the treatments differ.
Why is radiation used in such a young child? Radiation to the tumor bed lowers the chance the cancer returns locally and is part of the combined treatment that has greatly improved survival. In young children, the radiation is carefully planned at the lowest effective dose, and techniques such as proton therapy can protect growing tissues. Your child's team will explain how they minimize long-term effects.
What is the outlook? Much better than it used to be. With modern combined treatment — surgery, intensive chemotherapy, and radiation — the great majority of children with localized clear cell sarcoma of the kidney are cured, and even children with spread can do well. Because late relapses can occur, long-term follow-up is part of the plan.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- National Wilms Tumor Study / Children's Oncology Group renal tumor trials (no indexed identifier — see your care team) ↩
- Pediatric renal tumor molecular pathology literature (2015–2023) (no indexed identifier — see your care team) ↩
- Childhood renal tumor follow-up studies (2016–2024) (no indexed identifier — see your care team) ↩